Vivos Therapeutics (VVOS) Price to Book (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Price to Book for 7 consecutive years, with 1.64 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Book fell 132.48% year-over-year to 1.64 in Q2 2026; TTM through Jun 2026 was 1.64, a 132.48% decrease from a year earlier, with the FY2025 full-year figure at 12.16, down 482.89% from the prior year.
• Price to Book was 1.64 for Q2 2026 at Vivos Therapeutics, up from 12.56 in the prior quarter.
• Over five years, Price to Book peaked at 124.93 in Q3 2023 and troughed at 12.56 in Q1 2026.
• A 5-year average of 11.42 and a median of 2.59 in 2024 frame the typical range for Price to Book.
• Across the five-year window, Price to Book soared 8131.1% in 2023 and sank 482.89% in 2025, its largest moves.
• Over 5 years, Price to Book stood at 1.93 in 2022, then soared by 1815.43% to 36.91 in 2023, then slumped by 91.39% to 3.18 in 2024, then sank by 482.89% to 12.16 in 2025, then soared by 86.51% to 1.64 in 2026.
• The last three Price to Book figures came in at 1.64 (Q2 2026), 12.56 (Q1 2026), and 12.16 (Q4 2025), per Business Quant data.